Mixed Messaging: Tier 2 Abuse-Deterrent Opioid Claim Illusive
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s description of Purdue’s Targiniq abuse-deterrent mechanism seems to match up with a Tier 2 claim that the company didn’t receive, but the agency says this isn’t confusing.
You may also be interested in...
Opioid Market Snapshot: No Pain, No Gain For Abuse-Deterrence Claims
Abuse-deterrent opioids address a serious unmet need and help differentiate brands from the field of generics, but so far Purdue’s OxyContin remains the only opioid on the market with abuse-deterrent claims, even though FDA recently approved two new opioid analgesics.
FDA’s Opioid Guidance: Industry Celebrates Multi-Tiered Labeling Cake
Endo says label differentiation in the guidance is a positive step; Commissioner Hamburg tells Congress that if new opioid formulations “significantly” deter abuse, generic versions will have to as well.
Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length
Recently retired US FDA Principal Deputy Commissioner Janet Woodcock will be advising the Haystack Project, with the goal of helping rare disease organizations encourage creativity in drug development programs without jeopardizing regulatory success, Woodcock told the Pink Sheet in an interview.